NCT00605215已完成3 期
A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,331
- 试验地点
- 170
- 主要终点
- Annualized Rate of Confirmed Relapses
研究概览
简要总结
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria [Ann Neurol 2005: 58:840-846], with a relapsing-remitting disease course.
- •Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.
- •Subjects must be in a stable neurological condition between screening (month -1) and baseline visits (month 0).
- •Subjects must have had experienced one of the following:
- •At least one documented relapse in the 12 months prior to screening
- •At least two documented relapses in the 24 months prior to screening
- •One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior to screening.
- •Subjects must be between 18 and 55 years of age, inclusive.
- •Subjects must have disease duration of at least 6 months (from first symptom) prior to screening.
- •Women of child-bearing potential must practice 2 acceptable methods of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with spermicide)].
- •Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
排除标准
- •An onset of relapse or any treatment with corticosteroids (intravenous [iv], intramuscular [im] and/or per os [po]) or ACTH between month -1 (screening) and 0 (baseline).
- •Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
- •Use of immunosuppressive (including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.
- •Previous use of either of the following: natalizumab (Tysabri®), cladribine or laquinimod.
- •Previous treatment with glatiramer acetate (Copaxone®) or IVIG within 3 months prior to screening visit.
- •Previous treatment with Interferon beta-1a (Avonex® or Rebif®) or Interferon beta-1b (Betaseron®).
- •Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.
- •Previous total body irradiation or total lymphoid irradiation.
- •Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
- •A known history of tuberculosis.
- •Acute infection 2 weeks prior to baseline visit.
- •Major trauma or surgery 2 weeks prior to baseline visit.
- •A history of vascular thrombosis (excluding catheter-site superficial venous thrombophlebitis).
- •A carrier state of factor V Leiden mutation (either homo- or heterozygous) by history or as disclosed at screening.
- •Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody as disclosed at screening visit.
- •Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (see detailed list of drugs in protocol) (1 month for fluoxetine).
- •Use of amiodarone within 2 years prior to screening visit.
- •Pregnancy or breastfeeding.
- •Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:
- •A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.
- •A gastrointestinal disorder that may affect the absorption of study medication.
- •Renal, metabolic, endocrinological or hematological diseases.
- •Any form of chronic liver disease, including known non-alcoholic steatohepatitis.
- •A ≥2xULN serum elevation of either of the following at screening: ALT, AST or direct bilirubin.
- •A QTc interval (obtained from either two ECG recordings at screening or from the mean value calculated from three measurements at baseline visit) which is ≥450msec.
- •A family history of Long-QT syndrome.
- •A history of drug and/or alcohol abuse.
- •Major psychiatric disorder.
- •A history of a convulsive disorder.
- •Known hypersensitivity to either of the following: mannitol, meglumine or sodium stearyl fumarate.
- •Known hypersensitivity that would preclude administration of laquinimod.
- •The subject's inability to give informed consent, or to complete the study, or if the subject is considered by the investigator to be, for any reason, an unsuitable candidate for this study.
- •A known history of sensitivity to Gadolinium.
- •Inability to successfully undergo MRI scanning.
- •A known history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation of Avonex®.
- •Subjects who suffer from any form of progressive MS
- •Any condition which the investigator feels may interfere with participation in the study
- •Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation
- •Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
- •Previous treatment with immunomodulators within two months prior to screening
- •Pregnancy or breastfeeding
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive 1 capsule of placebo matching to laquinimod orally once daily for 24 months.
干预措施: Placebo (Drug)
Laquinimod
Experimental
Participants will receive 1 capsule of laquinimod 0.6 mg orally once daily for 24 months.
干预措施: Laquinimod (Drug)
Avonex®
Active Comparator
Participants will receive an injection of Avonex® 30 micrograms (mcg) given intramuscularly (IM) once weekly for 24 months.
干预措施: Avonex® (Drug)
结局指标
主要结局
Annualized Rate of Confirmed Relapses
时间窗: Baseline up to Month 24
A relapse was defined as the appearance of new neurological abnormalities or the reappearance of previously observed neurological abnormalities; lasting at least 48 hours and immediately preceded by an improved neurological state of ≥30 days from onset of previous relapse, accompanied by observed objective neurological changes (an increase of ≥0.5 in Expanded Disability Status Scale \[EDSS\] score, or an increase of 1 grade in the score of 2 or more of the 7 Functional Systems \[FS\], or an increase of 2 grades in the score of 1 FS as compared to the previous evaluation). Total number of confirmed relapses during the treatment period was divided by the sum of number of days on study in the treatment period and then multiplied by the number of days in the year to calculate the annualized relapse rate. Annualized relapse rate was derived from a baseline-adjusted negative binomial regression.
次要结局
- Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score(Baseline, Month 24)
- Accumulation of Physical Disability Measured by the Number of Participants With Confirmed Progression of EDSS(Baseline up to Month 24)
- Percent Change From Baseline in Brain Volume(Baseline, Month 24)
研究者
研究点 (170)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)Multiple SclerosisNCT00509145Teva Branded Pharmaceutical Products R&D, Inc.1,106
已完成
2 期
Laquinimod Phase IIa Study in Active Crohn's DiseaseCrohn's DiseaseNCT00737932Teva Branded Pharmaceutical Products R&D, Inc.180
已完成
2 期
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus ArthritisLupus ArthritisNCT01085084Teva Branded Pharmaceutical Products R&D, Inc.82
已完成
2 期
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus NephritisLupus NephritisNCT01085097Teva Branded Pharmaceutical Products R&D, Inc.46
已完成
2 期
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of LaquinimodHuntington's DiseaseNCT02215616Teva Branded Pharmaceutical Products R&D, Inc.352